Leadership Overview
Divi's Laboratories has 4 executives leading key functions including strategy, operations, financial management, and digital infrastructure.
Focused on global pharmaceutical excellence, Divi's Laboratories delivers high-quality generic APIs and nutraceutical ingredients while maintaining a commitment to advanced chemical synthesis and sustainable manufacturing practices across international markets.
Focused on global pharmaceutical excellence, Divi's Laboratories delivers high-quality generic APIs and nutraceutical ingredients while maintaining a commitment to advanced chemical synthesis and sustainable manufacturing practices across international markets.
Leadership Roles at Divi's Laboratories
Kiran Divi - Chief Executive Officer
Kiran Divi, the Chief Executive Officer at Divi's Laboratories, directs the overarching strategic vision for the organization. Overseeing the production of generic APIs and complex intermediates, the Chief Executive Officer ensures alignment between manufacturing capabilities and global pharmaceutical demand. This leadership role involves navigating competitive landscapes while maintaining rigorous quality standards across all facilities. By optimizing supply chain efficiency, Kiran Divi directly impacts the company's ability to scale production for international clients. The Chief Executive Officer also coordinates with the Board to prioritize long-term research investments. Through constant evaluation of market trends, Divi secures the competitive positioning of the firm within the pharmaceutical sector. This executive leadership maintains a focus on operational excellence, ensuring that the manufacturing processes remain at the forefront of industry innovation while supporting the broader mission of delivering essential health solutions to diverse global markets.
Kishorebabu Lingamneni - Chief Financial Officer
Kishorebabu Lingamneni, the Chief Financial Officer at Divi's Laboratories, manages the fiscal health and capital allocation strategies of the organization. Overseeing financial reporting, risk management, and investor relations, the Chief Financial Officer ensures the stability of the company's balance sheet. This leadership role involves analyzing market volatility to protect the firm's interests during large-scale pharmaceutical manufacturing expansions. By optimizing capital expenditure, Kishorebabu Lingamneni directly impacts the company's growth trajectory and shareholder value. The Chief Financial Officer also works closely with the executive team to align budgetary resources with long-term strategic goals. Through meticulous oversight of financial operations, Lingamneni secures the necessary funding for ongoing research and development initiatives. This executive leadership maintains a disciplined approach to fiscal management, ensuring that the organization possesses the financial resilience required to navigate the complexities of the global pharmaceutical market while sustaining consistent profitability and operational efficiency.
Manoranjan Jasti - Chief Information Officer
Manoranjan Jasti, the Chief Information Officer at Divi's Laboratories, directs the digital transformation and technological infrastructure of the enterprise. Overseeing the integration of advanced data systems, the Chief Information Officer ensures that manufacturing processes benefit from real-time analytics and secure information management. This leadership role involves protecting critical intellectual property through robust cybersecurity protocols while enhancing operational transparency across all facilities. By modernizing the digital architecture, Manoranjan Jasti directly impacts the efficiency of the supply chain and the accuracy of production data. The Chief Information Officer also collaborates with other executives to implement software solutions that streamline internal workflows and improve cross-departmental communication. Through the deployment of scalable IT systems, Jasti supports the company's ability to meet the demands of a global client base. This executive leadership ensures that the organization leverages technology to maintain a competitive edge in the pharmaceutical manufacturing industry.
Murali Divi - Managing Director
Murali Divi, the Managing Director at Divi's Laboratories, architects the foundational scientific and operational frameworks that define the company. Overseeing the custom synthesis division, the Managing Director drives technical innovation in the development of nutraceutical ingredients and pharmaceutical intermediates. This leadership role involves managing complex technical teams to ensure that every product meets stringent regulatory requirements. By fostering a culture of scientific rigor, Murali Divi directly impacts the company's reputation for quality and reliability. The Managing Director also collaborates with executive leadership to expand the footprint of the firm in emerging markets. Through the implementation of advanced chemical engineering practices, Divi maintains the technical superiority of the manufacturing infrastructure. This executive leadership ensures that the organization remains agile, consistently delivering high-value chemical solutions that address the evolving needs of the global healthcare industry while upholding the highest standards of corporate governance.
Explore Leadership Teams in Manufacturing
Zoetis discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company offers vaccines, medicated feed additives that offer medicines to livestock; and other pharmaceutical products, which comprise allergy and dermatology, pain and sedation, antiemetic, reproductive, and oncology products. It markets to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company is headquartered in Parsippany, New Jersey.
Company Leadership LP
RV
SA
MT
Eris Lifesciences Ltd is a prominent Indian pharmaceutical company specializing in branded formulations, particularly in the cardio-metabolic sector. The company offers a diverse range of products across various therapeutic areas including anti-diabetes, cardiovascular health, dermatology, and gynecology. Eris is committed to improving patient care through innovative initiatives and pioneering studies aimed at chronic lifestyle-related diseases. Their target clients include healthcare professionals and patients across India, with a focus on enhancing health outcomes.
Company Leadership GA
MM
VK
Soft gelatin capsule products, liquid preparations, medicinal plasters, ointments, and creams are produced at the Gunung Putri Plant. In producing these products, Gunung Putri Plant implements an Integrated Management System and has obtained ISO 9001:2015, ISO 14001:2015, ISO 45001:2018 and ISO 22000:2018 certificates. Meanwhile, sterile injection products and solid preparations in the form of tablets and capsules are produced at the Citeureup Plant. The Citeureup Plant also implements an Integrated Management System and has obtained ISO 9001:2015, ISO 14001:2015, ISO 45001:2018, and SNI ISO/IEC 17025:2017 certificates. In running the Toll Manufacturing business, Darya-Varia collaborates with an affiliated company, PT Medifarma Laboratories, at the Cimanggis Depok Plant. The Company has been trusted by local business partners and both for the domestic and international markets for the Export & Toll Manufacturing business and conducts technology transfer, lab and pilot trials, stability studies, procurement of raw materials and packaging, and commercial production of high-quality finished goods. Darya-Varia always ensures the quality and safety of each product, so that all of its products are certified halal. All plant facilities owned by Darya-Varia have implemented the halal guarantee system. Blue Sphere Singapore Pte Ltd (BSSPL) owns 92.13% stake in Darya-Varia. For 45 years, Darya-Varia has continued to progress in providing high quality health facilities. Through the mission of "building a healthier Indonesia for everyone one person at a time", Darya-Varia is always committed to providing a variety of quality products with the right strategy for the health of the Indonesian people. DARYA VARIA
Company Leadership CH
OrchidPharma Ltd is a vertically integrated pharmaceutical company with established research, manufacturing, and marketing capabilities across multiple therapeutic domains in healthcare. The company aims to build a sustainable organizational ecosystem that motivates individuals to achieve new heights and discover growth avenues. OrchidPharma is driven by values such as innovation and corporate social responsibility, alongside its strategic goals. Its intended clients include healthcare providers and organizations seeking comprehensive pharmaceutical solutions.
Company Leadership KP
NA
PP
MS
Frequently Asked Questions Regarding Divi's Laboratories Top Executives and Leadership Team
